These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 36593888)

  • 21. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization.
    Wagenpfeil J; Kupczyk PA; Bruners P; Siepmann R; Guendel E; Luetkens JA; Isaak A; Meyer C; Kuetting F; Pieper CC; Attenberger UI; Kuetting D
    Front Radiol; 2024; 4():1346550. PubMed ID: 38445105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma.
    Reincke M; Schultheiss M; Doppler M; Verloh N; Uller W; Sturm L; Thimme R; Goetz C; Bettinger D
    Hepatol Commun; 2022 Nov; 6(11):3223-3233. PubMed ID: 36064940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients.
    Yim SY; Chun HS; Lee JS; Lim JH; Kim TH; Kim BK; Kim SU; Park JY; Ahn SH; Kim GM; Won JY; Seo YS; Kim YH; Um SH; Kim DY
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.
    Loffroy R; Ronot M; Greget M; Bouvier A; Mastier C; Sengel C; Tselikas L; Arnold D; Maleux G; Pelage JP; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; Urdániz M; Kaufmann N; Bilbao JI; Helmberger T; Vilgrain V;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):36-49. PubMed ID: 32975600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study.
    Salem R; Garin E; Boucher E; Fowers K; Lam M; Padia S; Harris W
    Oncologist; 2024 Aug; 29(8):681-689. PubMed ID: 38985849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.
    Kim MA; Jang H; Choi NR; Nam JY; Lee YB; Cho EJ; Lee JH; Yu SJ; Kim HC; Chung JW; Yoon JH; Kim YJ
    J Hepatocell Carcinoma; 2021; 8():1565-1577. PubMed ID: 34909425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
    Cappelli A; Pettinato C; Golfieri R
    J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.
    McGee HM; King MJ; Özbek U; Olson A; Kim E; Fischman AM; Schwartz M; Rosenzweig KE; Buckstein M
    Am J Clin Oncol; 2019 Apr; 42(4):367-374. PubMed ID: 30724782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
    Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
    J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study.
    Bayona Molano MDP; Kolber M; Barrera JV; Akram MR; Alnablsi MW; Pothini T; Salem R; Singal AG
    Cureus; 2024 Jun; 16(6):e61904. PubMed ID: 38855496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients.
    Chung SW; Cho H; Shin H; Park J; Kim JY; Hong JH; Hur MH; Park MK; Lee YB; Yu SJ; Lee M; Kim YJ; Paeng JC; Yoon JH; Chung JW; Lee JH; Kim HC
    Front Oncol; 2023; 13():1081479. PubMed ID: 36925930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
    Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
    JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
    Martelletti C; Ricotti A; Gesualdo M; Carucci P; Gaia S; Rolle E; Burlone ME; Okolicsanyi S; Mattalia A; Pirisi M; Berchialla P; Tabone M
    J Dig Dis; 2021 Aug; 22(8):496-502. PubMed ID: 34189839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.